Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

[1]  Nicola J. Ray,et al.  Cholinergic white matter pathways in dementia with Lewy bodies and Alzheimer’s disease , 2021, Brain : a journal of neurology.

[2]  B. Boeve,et al.  Outcome Measures for Dementia With Lewy Body Clinical Trials , 2021, Alzheimer disease and associated disorders.

[3]  Matthew D. Zammit,et al.  Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease , 2021, Frontiers in Aging Neuroscience.

[4]  C. Sorg,et al.  Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia , 2021, Neuropsychopharmacology.

[5]  P. Scheltens,et al.  A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease , 2021, Alzheimer's Research & Therapy.

[6]  Alan J. Thomas,et al.  In vivo nucleus basalis of Meynert degeneration in mild cognitive impairment with Lewy bodies , 2021, NeuroImage: Clinical.

[7]  Nicola J. Ray,et al.  Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[8]  P. Brown,et al.  Cortical connectivity of the nucleus basalis of Meynert in Parkinson’s disease and Lewy body dementias , 2020, Brain : a journal of neurology.

[9]  E. Londos,et al.  Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.

[10]  U. Germann,et al.  Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level , 2020, PloS one.

[11]  N. Müller,et al.  Structural MRI of the basal forebrain as predictor of cognitive response to galantamine in healthy older adults: A randomized controlled double‐blinded crossover study , 2020 .

[12]  J. Smiley,et al.  Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer's Disease. , 2020, Cell reports.

[13]  H. Bronte-Stewart,et al.  Gait variability is linked to the atrophy of the Nucleus Basalis of Meynert and is resistant to STN DBS in Parkinson’s disease , 2020, Neurobiology of Disease.

[14]  A. Ittner,et al.  Functions of p38 MAP Kinases in the Central Nervous System , 2020, Frontiers in Molecular Neuroscience.

[15]  T. Druzgal,et al.  Cholinergic nucleus 4 atrophy and gait impairment in Parkinson’s disease , 2020, Journal of Neurology.

[16]  N. Bohnen,et al.  Topography of Cholinergic Changes in Dementia With Lewy Bodies and Key Neural Network Hubs. , 2020, The Journal of neuropsychiatry and clinical neurosciences.

[17]  Clara S. Tang,et al.  Cholinergic suppression of sharp wave-ripples impairs hippocampus-dependent spatial memory , 2020, bioRxiv.

[18]  J. Trojanowski,et al.  Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology , 2019, Neuron.

[19]  O. Pedraza,et al.  Selective Vulnerability of the Nucleus Basalis of Meynert Among Neuropathologic Subtypes of Alzheimer Disease , 2019, JAMA neurology.

[20]  E. Masliah,et al.  Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies–like model , 2019, Alzheimer's & Dementia.

[21]  A. Cuervo,et al.  Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) , 2019, The Journal of Neuroscience.

[22]  Taylor W. Schmitz,et al.  Basal forebrain volume reliably predicts the cortical spread of Alzheimer’s degeneration , 2019, bioRxiv.

[23]  W. Mobley,et al.  Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses , 2019, Front. Neurosci..

[24]  J. Myslivecek,et al.  Variability in the Drug Response of M4 Muscarinic Receptor Knockout Mice During Day and Night Time , 2019, Front. Pharmacol..

[25]  M. Mendez.  Early-onset Alzheimer Disease and Its Variants , 2019, Continuum.

[26]  C. Davies,et al.  Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS , 2018, Cell Death & Disease.

[27]  Yue Huang,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.

[28]  D. Salmon,et al.  Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study , 2017, Alzheimer's & dementia.

[29]  R. Nixon.  Amyloid precursor protein and endosomal‐lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  E. Masliah,et al.  Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease , 2017, Scientific Reports.

[31]  Magnus Andersson,et al.  ToxTrac: A fast and robust software for tracking organisms , 2017, ArXiv.

[32]  A. Nebreda,et al.  Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer’s mouse model by controlling β-amyloid production , 2017, Scientific Reports.

[33]  Alan J. Thomas,et al.  Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB , 2017, Neurology.

[34]  E. Masliah,et al.  Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy , 2017, Acta neuropathologica communications.

[35]  Sterling C. Johnson,et al.  Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology , 2016, Nature Communications.

[36]  W. Scheper,et al.  Targeting neuronal MAPK14/p38α activity to modulate autophagy in the Alzheimer disease brain , 2016, Autophagy.

[37]  S. Lehéricy,et al.  Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease , 2016, Neuropharmacology.

[38]  J. Smiley,et al.  Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF , 2016, Neurobiology of Aging.

[39]  K. Fassbender,et al.  Deficiency of Neuronal p38α MAPK Attenuates Amyloid Pathology in Alzheimer Disease Mouse and Cell Models through Facilitating Lysosomal Degradation of BACE1* , 2015, The Journal of Biological Chemistry.

[40]  Keith A. Johnson,et al.  Massachusetts Alzheimer's Disease Research Center: Progress and challenges , 2015, Alzheimer's & Dementia.

[41]  J. Alam.  Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats , 2015, Journal of Alzheimer's disease : JAD.

[42]  N. Iwata,et al.  Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis , 2015, The international journal of neuropsychopharmacology.

[43]  R. Nixon,et al.  Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease , 2015, Molecular Psychiatry.

[44]  M. L. Seibenhener,et al.  Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. , 2015, Journal of visualized experiments : JoVE.

[45]  Stefan J. Teipel,et al.  Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer’s disease dementia , 2014, Journal of Neurology.

[46]  M. Ohno,et al.  Glutamatergic Transmission Aberration: A Major Cause of Behavioral Deficits in a Murine Model of Down's Syndrome , 2014, The Journal of Neuroscience.

[47]  A. Nebreda,et al.  SnapShot: p38 MAPK Substrates , 2013, Cell.

[48]  E. Dobrikova,et al.  p38α Mitogen-Activated Protein Kinase Depletion and Repression of Signal Transduction to Translation Machinery by miR-124 and -128 in Neurons , 2012, Molecular and Cellular Biology.

[49]  J. Arthur,et al.  p38α and p38β Mitogen-Activated Protein Kinases Determine Cholinergic Transdifferentiation of Sympathetic Neurons , 2011, The Journal of Neuroscience.

[50]  L. V. Van Eldik,et al.  The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS. , 2010, Aging and disease.

[51]  Kerry A. Mullaney,et al.  Alzheimer’s-related endosome dysfunction in Down syndrome is Aβ-independent but requires APP and is reversed by BACE-1 inhibition , 2009, Proceedings of the National Academy of Sciences.

[52]  Matti Pastell,et al.  CowLog: Open-source software for coding behaviors from digital video , 2009, Behavior research methods.

[53]  R. Neve,et al.  Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. , 2008, The American journal of pathology.

[54]  F. Schmidt.  Meta-Analysis , 2008 .

[55]  M. Tuszynski,et al.  The Basal Forebrain Cholinergic System Is Essential for Cortical Plasticity and Functional Recovery following Brain Injury , 2005, Neuron.

[56]  Mara Dierssen,et al.  Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome , 2004, Brain Research.

[57]  Ian G. McKeith,et al.  Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies , 2004, Dementia and Geriatric Cognitive Disorders.

[58]  J. Duda.  Pathology and Neurotransmitter Abnormalities of Dementia with Lewy Bodies , 2003, Dementia and Geriatric Cognitive Disorders.

[59]  C. Epstein,et al.  App Gene Dosage Modulates Endosomal Abnormalities of Alzheimer's Disease in a Segmental Trisomy 16 Mouse Model of Down Syndrome , 2003, The Journal of Neuroscience.

[60]  M. Poo,et al.  Acetylcholine-secreting cells improve age-induced memory deficits. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[61]  M. Giovannini,et al.  The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo , 2003, Neuroscience.

[62]  G. Niewiadomska,et al.  Amelioration of cholinergic neurons dysfunction in aged rats depends on the continuous supply of NGF , 2002, Neurobiology of Aging.

[63]  I. McKeith,et al.  Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System , 2002, Dementia and Geriatric Cognitive Disorders.

[64]  Jiahuai Han,et al.  MAPKK-Independent Activation of p38α Mediated by TAB1-Dependent Autophosphorylation of p38α , 2002, Science.

[65]  Ahmad Salehi,et al.  Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[66]  J. Wess,et al.  Hyperactivity and Intact Hippocampus-Dependent Learning in Mice Lacking the M1 Muscarinic Acetylcholine Receptor , 2001, The Journal of Neuroscience.

[67]  M. Karin,et al.  The stress-induced MAP kinase p38 regulates endocytic trafficking via the GDI:Rab5 complex. , 2001, Molecular cell.

[68]  Philippe P Roux,et al.  NRAGE, A Novel MAGE Protein, Interacts with the p75 Neurotrophin Receptor and Facilitates Nerve Growth Factor–Dependent Apoptosis , 2000, Neuron.

[69]  B T Hyman,et al.  Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. , 2000, The American journal of pathology.

[70]  D. Holtzman,et al.  Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[71]  H. Gundersen,et al.  Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator , 1991, The Anatomical record.

[72]  OUP accepted manuscript , 2022, Brain Communications.

[73]  Harald Hampel,et al.  Revisiting the Cholinergic Hypothesis in Alzheimer’s Disease: Emerging Evidence from Translational and Clinical Research , 2018, The Journal of Prevention of Alzheimer's Disease.

[74]  M. Giovannini,et al.  The Role of Cholinergic System in Novel Object Recognition , 2018 .

[75]  L. Bracco,et al.  Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients. , 2014, Journal of Alzheimer's disease : JAD.

[76]  Jiahuai Han,et al.  MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. , 2002, Science.

[77]  Robert C. Wolpert,et al.  A Review of the , 1985 .